UNSPSC 51141590: Donepezil hydrochloride

This classification denotes a cholinesterase inhibitor and nootropic agent with the molecular formula C24H29NO3.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3O2T2PJ89D, chemically known as 1h-inden-1-one, 2,3-dihydro-5,6-dimethoxy-2-((1-(phenylmethyl)-4-piperidinyl)methyl)-, hydrochloride but more generally known as donepezil hydrochloride, which bears US NIH Compound Identifier 5741.

UNSPSC 51141590 Donepezil hydrochloride is a Commodity code identifying a specific pharmaceutical product, yet recent state and local opportunities posted under this code show substantial mismatch: solicitations are for naloxone, multi-source generic pharmaceuticals and OTC products, and direct-to-manufacturer prescription program infrastructure — not donepezil specifically. State and local governments buying under this code tier are procuring pharmaceuticals and related pharmacy services through a mix of issuing bodies including county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS), and cooperative purchasing alliances serving multiple jurisdictions (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP). When pharmaceutical-specific opportunities do materialize, they typically involve bulk purchasing through authorized wholesalers, compliance with FDA and cGMP standards, and multi-year contract terms with renewal options.

Recent activity spans Florida, Texas, Minnesota, and Oregon. The Seminole County, Florida IFB (IFB60459723LAS) sought 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, due July 26, 2023. The Texas HHS Commission issued an RFI (HHS0017013) in April 2026 to explore direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization channels, signaling potential future procurement in this space. The Minnesota Multistate Cooperative Purchasing Alliance released an RFP (S1070000015802) in January 2026 for generic multi-source pharmaceuticals and OTC products distributed across state and local facilities, with proposals due March 26, 2026, emphasizing price competitiveness (75 percent of evaluation weight), cGMP compliance, and relationships with authorized wholesalers including AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson.